Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
Élisabeth Maillart, Caroline Papeix, Catherine Lubetzki, Thomas Le Roux, Valérie Pourcher, Céline Louapre
Topics & Concepts
MedicineNeuromyelitis opticaCoronavirus disease 2019 (COVID-19)Multiple sclerosisCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Serology2019-20 coronavirus outbreakImmunologyAntibodyVirologyInternal medicineDiseaseOutbreakInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesLong-Term Effects of COVID-19